Additionally, the EMPA-KIDNEY trial demonstrated reduced risk of progression of kidney disease in individuals with chronic kidney disease with use of SGLT2-i which ultimately led to FDA approval for use in chronic kidney disease regardless of diabetes status [19]. This evidence concerns the gene SLC5A2 and diabetes mellitus.